• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy

tetano

Editor, Senior Moderator
Vaccine


. 2021 Sep 14;S0264-410X(21)01149-X.
doi: 10.1016/j.vaccine.2021.08.089. Online ahead of print.
Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy


Do-Young Kim[SUP] 1 [/SUP], Yong-Myung Kang[SUP] 1 [/SUP], Hyun-Kyu Cho[SUP] 1 [/SUP], Seo-Jeong Park[SUP] 1 [/SUP], Myoung-Heon Lee[SUP] 1 [/SUP], Youn-Jeong Lee[SUP] 1 [/SUP], Hyun-Mi Kang[SUP] 2 [/SUP]



Affiliations

Abstract

Since June 2020, a new H9N2 virus of the Y280 lineage has been epidemic in Korea. Initially, a Korean commercial vaccine against the Y280 and Y439 lineages of H9N2 was evaluated for use in SPF chickens. A single vaccination did not protect chickens against virus of the Y280 lineage, with no significant reduction in virus shedding and a 37.5% inhibition in virus recovery rate in cecal tonsil. rgHS314 was selected as a vaccine candidate, showing immunogenicity in SPF chickens, and was highly productive in eggs. Moreover, rgHS314 protected with high levels of protective immunity and significantly reduced virus shedding, with 100% and 83.3% inhibition of virus recovery in the cecal tonsil against homologous and heterologous challenge viruses, respectively. Taken together, these data suggest that a single vaccination with this recombinant vaccine candidate could elicit cross-reactive immune responses capable of protecting chickens against H9N2 viruses of the Y439 and Y280 lineages.

Keywords: Antigen cartography; H9N2; Reverse genetics; Vaccine; Y280 lineage.
 
Back
Top Bottom